Machine learning models to accelerate the design of polymeric long-acting injectables

被引:77
|
作者
Bannigan, Pauric [1 ]
Bao, Zeqing [1 ]
Hickman, Riley J. [2 ,3 ,4 ]
Aldeghi, Matteo [2 ,3 ,4 ]
Hase, Florian [2 ,3 ,4 ]
Aspuru-Guzik, Alan [2 ,3 ,4 ,5 ,6 ,7 ]
Allen, Christine [1 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 3M2, Canada
[2] Univ Toronto, Dept Comp Sci, Toronto, ON M5S 3H6, Canada
[3] Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON M5S 3E5, Canada
[4] Vector Inst Artificial Intelligence, Toronto, ON M5S 1M1, Canada
[5] Univ Toronto, Dept Mat Sci & Engn, Toronto, ON M5S 3E4, Canada
[6] Canadian Inst Adv Res, Toronto, ON M5S 1M1, Canada
[7] Vector Inst, CIFAR Artificial Intelligence Res Chair, Toronto, ON M5S 1M1, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
IN-VITRO RELEASE; DRUG-DELIVERY SYSTEM; PACLITAXEL TAXOL(R); PLGA MICROPARTICLES; MICROSPHERES; FORMULATION; PHARMACOKINETICS; OSTEOARTHRITIS; DEXAMETHASONE; SUSPENSION;
D O I
10.1038/s41467-022-35343-w
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Long-acting injectables are considered one of the most promising therapeutic strategies for the treatment of chronic diseases as they can afford improved therapeutic efficacy, safety, and patient compliance. The use of polymer materials in such a drug formulation strategy can offer unparalleled diversity owing to the ability to synthesize materials with a wide range of properties. However, the interplay between multiple parameters, including the physicochemical properties of the drug and polymer, make it very difficult to intuitively predict the performance of these systems. This necessitates the development and characterization of a wide array of formulation candidates through extensive and time-consuming in vitro experimentation. Machine learning is enabling leap-step advances in a number of fields including drug discovery and materials science. The current study takes a critical step towards data-driven drug formulation development with an emphasis on long-acting injectables. Here we show that machine learning algorithms can be used to predict experimental drug release from these advanced drug delivery systems. We also demonstrate that these trained models can be used to guide the design of new long acting injectables. The implementation of the described data-driven approach has the potential to reduce the time and cost associated with drug formulation development. Polymer-based long-acting injectable drugs are a promising therapeutic strategy for chronic diseases. Here the authors use machine learning to inform the data-driven development of advanced drug formulations.
引用
收藏
页数:12
相关论文
共 50 条
  • [11] Long-Acting Injectables: Current Perspectives and Future Promise
    Chaudhary, Komal
    Patel, Mayur M.
    Mehta, Priti J.
    CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2019, 36 (02): : 137 - 181
  • [12] Leveraging Model Master Files for Long-Acting Injectables
    Gong, Yuqing
    Hopefl, Robert
    Li, Tonglei
    Hooker, Andrew C.
    Silva, Daniela Amaral
    Alam, Khondoker
    Ducharme, Murray
    Moody, Rebecca
    Saha, Pratik
    Babiskin, Andrew
    PHARMACEUTICAL RESEARCH, 2025,
  • [13] A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables
    Somayaji, Mahadevabharath R.
    Das, Debarun
    Przekwas, Andrzej
    CLINICAL PHARMACOKINETICS, 2016, 55 (10) : 1179 - 1190
  • [14] A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables
    Mahadevabharath R. Somayaji
    Debarun Das
    Andrzej Przekwas
    Clinical Pharmacokinetics, 2016, 55 : 1179 - 1190
  • [15] Free long-acting injectables for patients with psychosis: A step forward
    Kong, Ling-zhuo
    Shen, Yu-ting
    Zhang, Dan-hua
    Lai, Jian-bo
    Hu, Shao-hua
    ASIAN JOURNAL OF PSYCHIATRY, 2023, 83
  • [16] The use of long-acting injectables in early-phase schizophrenia
    Kane, John M.
    Kishimoto, Taishiro
    Achtyes, Eric
    Rubio, Jose
    Correll, Christoph
    LANCET PSYCHIATRY, 2023, 10 (07): : 480 - 481
  • [17] Long-Acting Ocular Injectables: Are We Looking In The Right Direction?
    Dang, Mickael
    Shoichet, Molly S.
    ADVANCED SCIENCE, 2024, 11 (08)
  • [18] Long-acting injectables for tuberculosis prophylaxis and treatment: is now the time?
    Dooley, Kelly E.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2018, 22 (08) : 833 - 834
  • [19] Long-Acting Injectables: A Strategy to Mitigate Nonadherence in Bipolar Disorder
    Faden, Justin
    Maymind, Elina
    BIPOLAR DISORDERS, 2025,
  • [20] Improving patient acceptance of maintenance treatment with long-acting injectables
    Potkin, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S617 - S617